慢性丙型肝炎抗病毒药物及其治疗方案研究进展

曾群; 揭盛华

doi:10.3969/j.issn.1001-5256.2017.11.033

慢性丙型肝炎抗病毒药物及其治疗方案研究进展

DOI: 10.3969/j.issn.1001-5256.2017.11.033

曾群,
揭盛华

华中科技大学同济医学院附属协和医院感染病科

详细信息

中图分类号: R512.63
计量
- 文章访问数: 2035
- HTML全文浏览量: 35
- PDF下载量: 441
- 被引次数: 0
出版历程
- 收稿日期: 2017-05-02
- 出版日期: 2017-11-20

Research advances in antiviral drugs and their treatment regimens in chronic hepatitis C

Department of Infectious Diseases, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

摘要

摘要: 慢性丙型肝炎成为全球严重的公共卫生问题,近年来随着丙型肝炎的药物治疗不断发展,使丙型肝炎治愈成为可能。从丙型肝炎的流行现状,传统的标准治疗方案（聚乙二醇干扰素+利巴韦林）以及不同的口服小分子直接抗病毒药物（DAAs）的优势及副作用,总结了不同DAAs药物组合对于不同慢性丙型肝炎基因型治疗的利弊,并简要介绍了世界卫生组织对于丙型肝炎治疗的推荐意见。相信未来慢性丙型肝炎的药物治疗会不断飞跃,消灭丙型肝炎指日可待。
- 肝炎,丙型,慢性 /
- 抗病毒药 /
- 治疗 /
- 综述
Abstract: Chronic hepatitis C has become a serious public health issue around the world.In recent years, with the development of pharmacotherapy for hepatitis C, it may be possible to cure hepatitis C.With reference to the epidemic status of hepatitis C and the advantages and side effects of conventional standard therapy (pegylated interferon plus ribavirin) and various oral direct-acting antiviral agents (DAAs) , this article summarizes the advantages and disadvantages of different combinations of DAAs in the treatment of chronic hepatitis C with different genotypes and briefly introduces the World Health Organization recommendations on the treatment of hepatitis C.Hepatitis C is expected to be eliminated with the development of pharmacotherapy for chronic hepatitis C.
- hepatitis C, chronic /
- antiviral agents /
- therapy /
- review

HTML全文

参考文献(41)

[1]MCCONACHIE SM, WILHELM SM, KALEPRADHAN PB.New direct-acting antivirals in hepatitis C therapy:a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir[J].Expert Rev Clin Phar, 2016, 9 (2) :287-302.

[2]PENG HY, YANG EN, SUN DX.Research advances in sofosbuvir for treatment of chronic hepatitis C[J].J Clin Hepatol, 2016, 32 (4) :798-801. (in Chinese) 彭焕彦, 杨二娜, 孙殿兴.索非布韦治疗慢性丙型肝炎的研究进展[J].临床肝胆病杂志, 2016, 32 (4) :798-801.

[3]ASSELAH T, BOYER N, SAADOUN D, et al.Direct-acting antivirals for the treatment of hepatitis C virus infection:optimizing current IFN-free treatment and future perspectives[J].Liver Int, 2016, 36 (Suppl 1) :47-57.

[4]LI Q, HUANG YX, CHEN L.Research progress of interferon free anti HCV regimen[J].J Clin Hepatol, 2016, 32 (1) :169-173. (in Chinese) 李强, 黄玉仙, 陈良.无干扰素抗HCV方案的研究进展[J].临床肝胆病杂志.2016, 32 (1) :169-173.

[5]HE YM, HOU B.PEG-IFNα-2a and ribavirin for decompensated cirrhotic patients with hepatitis C after eliminating complication[J].Chin J Med Offic, 2017, 45 (4) :397-400. (in Chinese) 何妍梅, 侯波.聚乙二醇干扰素啊α-2a联合利巴韦林治疗失代偿期丙肝肝硬化并发症消除后患者临床观察[J].临床军医杂志, 2017, 45 (4) :397-400.

[6]KONG WL, YANG YL, XU HQ, et al.Relationship between liver function and virological response in patients with chronic hepatitis Cduring antiviral treatment[J].J Jilin Univ:Med Edit, 2016, 42 (1) :99-103. (in Chinese) 孔文丽, 杨以良, 徐洪芹, 等.慢性丙型肝炎患者抗病毒治疗中肝功能与病毒学应答的关系[J].吉林大学学报:医学版, 2016, 42 (1) :99-103.

[7]CHANG CY, NGUYEN P, LE A, et al.Real-world experience with interferon-free, direct acting antiviral therapies in Asian A-mericans with chronic hepatitis C and advanced liver disease[J].Medicine, 2017, 96 (6) :e6128.

[8]RAO ZF, WANG WG, CHENG ZL, et al.Antiviral therapy for chronic hepatitis C complicated with cirrhosis[J].China Pharmacist, 2016, 19 (2) :357-359. (in Chinese) 饶志方, 王婉钢, 程振玲, 等.慢性丙型肝炎合并肝硬化的抗病毒方案[J].中国药师, 2016, 19 (2) :357-359.

[9]WANG YY, NIE QH.study of direct antiviral drugs and their treatment for chronic hepatitis C[J].Chin Hepatol, 2016, 21 (2) :140-142. (in Chinese) 王媛媛, 聂青和.直接抗病毒药物研究及其治疗慢性丙型肝炎现状[J].肝脏, 2016, 21 (2) :140-142.

[10]XIE Y.DAA era of antiviral therapy for chronic hepatic C and standard Peg IFN/RBV therapy in China[J/CD].Chin J Liver Dis:Electronic Edition, 2015, 7 (3) :40-41. (in Chinese) 谢尧.中国慢性丙型肝炎抗病毒治疗DAA时代与Peg IFN/RBV标准治疗[J/CD].中国肝脏病杂志:电子版, 2015, 7 (3) :40-41.

[11]NAKAMURA M, KANDA T, HAGA Y, et al.Sofosbuvir treatment and hepatitis C virus infection[J].World J Hepatol, 2016, 8 (3) :183-190.

[12]LEE LY, TONG CYW, WONG T, et al.New therapies for chronic hepatitis C infection:a systematic review of evidence from clinical trials[J].Int J Clin Pract, 2012, 66 (4) :342.

[13]CHEN JH, XU XY.Study on the related variants of direct antiviral drugs in hepatitis C[J].Infect Dis Info, 2016, 29 (2) :116-120. (in Chinese) 陈建宏, 徐小元.丙型肝炎直接抗病毒药物耐药相关变异的研究[J].传染病信息, 2016, 29 (2) :116-120.

[14]PHILIPP S, HEINER W.The new era of interferon-free treatment of chronic hepatitis C[J].Viszeralmedizin, 2015, 31 (4) :290-296.

[15]BHATIA HK, SINGH H, GREWAL N, et al.Sofosbuvir:a novel treatment option for chronic hepatitis C infection[J].J Pharmacol Pharmacother, 2014, 5 (4) :278-284.

[16]GREIG SL.Sofosbuvir/velpatasvir:a review in chronic hepatitis C[J].Drugs, 2016, 76 (16) :1-12.

[17]HEZODE C, CHEVALIEZ S, SCOAZEC G, et al.Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen[J].Hepatology, 2016, 63 (6) :1809.

[18]BANERJEE D, REDDY KR.Review article:safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis Ctherapy[J].Aliment Pharmacol Ther, 2016, 43 (6) :674-696.

[19]ELBAZ T, ELKASSAS M, ESMAT G.New era for management of chronic hepatitis C virus using direct antiviral agents:a review[J].J Adv Res, 2015, 6 (3) :301-310.

[20]ZHOU SN, ZHANG M.Metabolism and drug interaction of hepatitis C direct antiviral drugs[J].Infect Dis Info, 2016, 29 (2) :121-125. (in Chinese) 周双男, 张敏.丙型肝炎直接抗病毒药物的代谢及药物相互作用[J].传染病信息, 2016, 29 (2) :121-125.

[21]GRITSENKO D, HUGHES G.Ledipasvir/sofosbuvir (harvoni) :improving options for hepatitis C virus infection[J].P T, 2015, 40 (4) :256-576.

[22]MANNS M, POL S, JACOBSON IM, et al.All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b:a multinational, phase 3, multicohort study[J].Lancet, 2014, 384 (9954) :1597-1605.

[23]MORIO K, IMAMURA M, KAWAKAMI Y, et al.Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients[J].J Gastroenterol Hepatol, 2016, 32 (3) :645-650.

[24]SARRAZIN C.The importance of resistance to direct antiviral drugs in HCV infection in clinical practice[J].J Hepatol, 2016, 64 (2) :486-504.

[25]MCPHEE F, FRIBORG J, LEVINE S, et al.Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir[J].Antimicrob Agents Chemother, 2012, 56 (7) :3670-3681.

[26]LONTOK E, HARRINGTON P, HOWE A, et al.Hepatitis C virus drug resistance-associated substitutions:state of the art summary[J].Hepatology, 2015, 62 (5) :1623-1632.

[27]OGAWA E, FURUSYO N, NOMYRA H, et al.Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65and over with or without cirrhosis[J].Antiviral Res, 2016, 136:37-44.

[28]KOZUKA R, HAI H, TERANISHI Y, et al.ITPA polymorphism correlates with the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy[J].J Gastroenterol Hepatol, 2017, 32 (8) :1495-1502.

[29]ANNAROSA, FLOREANI.Hepatitis C and pregnancy[J].World JGastroenterol, 2013, 19 (40) :6714-6720.

[30]AFDHAL N, ZEUZEM S, KWO P, et al.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection[J].N Engl J Med, 2014, 370 (16) :1483-1493.

[31]OYA Y, SUGAWARA Y, WATANABE T, et al.Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation[J].Biosci Trends, 2017, 10 (6) :496-499.

[32]KOWDLEY KV, GORDON SC, REDDY KR, et al.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis[J].N Engl J Med, 2014, 370 (20) :1879-1888.

[33]WHO Guidelines Approved by the Guidelines Review Committee.Guidelines for the screening care and treatment of persons with chronic hepatitis C infection[G].World Health Organization, 2016:1-133.

[34]GAMAL N, GITTO S, ANDREONE P.Efficacy and safety of daclatasvir in hepatitis C:an overview[J].J Clin Transl Hepatol, 2016, 4 (4) :336-344.

[35]KARINO Y, TOYOTA J, IKEDA K, et al.Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.[J].JHepatol, 2013, 58 (4) :646-654.

[36]UCHIDA Y, KOUYAMA JI, NAIKI K, et al.Development of rare RAVs that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism[J].Hepatol Res, 2016, 46 (12) :1234-1246.

[37]LAWITZ E, SULKOWSK MS, GHALIB R, et al.Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients:the COSMOS randomised study[J].Lancet, 2014, 384 (9956) :1756-1765.

[38]CHAN HL, TSANG OT, HUI YT, et al.Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir in chronic hepatitis C patients in Hong Kong[J].J Gastroenterol Hepatol, 2017, 32 (6) :1230-1233.

[39]EVERSON GT, TOWNER WJ, DAVIS MN, et al.Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1to 6 hepatitis C virus infection:a randomized trial[J].Ann Intern Med, 2015, 163 (11) :818-826.

[40]FELD JJ, JACOBSON IM, HEZODE C, et al.Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection[J].N Engl J Med, 2015, 373 (27) :2599.

[41]LAWITZ E, POORDAD F, WELLS J, et al.Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in DAA-experienced patients with genotype 1 HCV[J].Hepatology, 2017, 65 (6) :1803-1809.

施引文献

资源附件(0)

访问统计